ArticleWorld journal of psychiatry2025
Application and efficacy of quetiapine in patients with high-risk factors for bipolar disorder: A randomized controlled trial.
Article in World journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBipolar disorder (BD), marked by recurring manic and depressive episodes, often coexists with anxiety disorder (AD), which increases treatment complexity and morbidity. Although quetiapine, an atypical antipsychotic, has demonstrated efficacy in treating BD and AD, further investigation is needed regarding its effectiveness and safety in patients with AD at high-risk factors for BD.
aimTo explore the application and efficacy of quetiapine in combination therapy for patients with AD at high-risk factors for BD.
methodsThis study included 67 patients, with two excluded, leaving 65 divided into Group A (sertraline treatment) and Group B (combination treatment). All patients received sertraline, with Group B additionally receiving quetiapine. Efficacy was assessed using the Hamilton anxiety scale (HAMA), Hamilton depression scale (HAMD), and Bech-Rafaelsen Mania sale (BRMS) throughout the treatment period. Side effects and physiological indicators were also monitored.
resultsNo significant baseline differences existed between the two groups at treatment onset. Over the treatment course, Group B exhibited significantly lower HAMA scores than Group A at the end of weeks 1 and 24. HAMD scores gradually decreased over time, with Group B consistently showing lower scores than Group A. BRMS scores decreased significantly from baseline by week 8. In Group A, 27.27% of patients received zolpidem treatment compared to 10.53% in Group B, which was a significant difference. Incidence of adverse reactions did not differ significantly between groups at treatment onset, but most patients experienced relief from adverse reactions within 4 weeks.
conclusionCombination of quetiapine and sertraline can more rapidly alleviate anxiety and depressive symptoms in patients with AD at high-risk factors for BD, improving treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.